We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Amplia Therapeutics Limited is a biotechnology business based in Australia. Amplia Therapeutics shares (ATX) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Amplia Therapeutics has a trailing 12-month revenue of around $1.5 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $0.175 - $0.37 |
|---|---|
| 50-day moving average | $0.2039 |
| 200-day moving average | $0.2218 |
| Target price | $0.73 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.024 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.205
| 1 week (2021-10-15) | 5.13% |
|---|---|
| 1 month (2021-09-22) | 10.81% |
| 3 months (2021-07-22) | -4.65% |
| 6 months (2021-04-22) | -18.00% |
| 1 year (2020-10-22) | -24.07% |
|---|---|
| 2 years (2019-10-22) | 150.00% |
| 3 years (2018-10-22) | -29.31% |
| 5 years (2016-10-21) | -99.72% |
| Revenue TTM | $1.5 million |
|---|---|
| Gross profit TTM | $1.2 million |
| Return on assets TTM | -14.63% |
| Return on equity TTM | -24.08% |
| Profit margin | -148.75% |
| Book value | 0.096 |
| Market capitalisation | $24.3 million |
TTM: trailing 12 months
We're not expecting Amplia Therapeutics to pay a dividend over the next 12 months.
Amplia Therapeutics's shares were split on a 1:10 basis on 29 April 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Amplia Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Amplia Therapeutics shares which in turn could have impacted Amplia Therapeutics's share price.
Over the last 12 months, Amplia Therapeutics's shares have ranged in value from as little as $0.175 up to $0.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Amplia Therapeutics's is 0.386. This would suggest that Amplia Therapeutics's shares are less volatile than average (for this exchange).
Amplia Therapeutics Limited, a pharmaceutical company, engages in the development of focal adhesion kinase (FAK) inhibitors in Australia. The company is developing inhibiting drug candidates, including AMP886 and AMP945 for oncology and chronic fibrosis indications. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Shares in the wealth management giant have been largely stable in the last 6 months.
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
Everything we know about the Artrya IPO, plus information on how to buy in.
Everything we know about the 8 Au IPO, plus information on how to buy in.
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
The online retailer’s shares have lost more than half their value in the last 12 months.
